BR0308071A - Inibidores da protéina farnesil transferase como agentes antitumores - Google Patents

Inibidores da protéina farnesil transferase como agentes antitumores

Info

Publication number
BR0308071A
BR0308071A BR0308071-4A BR0308071A BR0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A
Authority
BR
Brazil
Prior art keywords
compounds
protein inhibitors
formula
farnesyl transferase
transferase protein
Prior art date
Application number
BR0308071-4A
Other languages
English (en)
Inventor
Hugh Y Zhu
F George Njoroge
Alan B Cooper
Timothy J Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A Pinto
Bancha Vibulbhan
Kartik M Keertikar
Carmen S Alvarez
John J Baldwin
Ge Li
Huang Chia-Yu
Ray A James
W Robert Bishop
James J-S Wang
Jagdish A Desai
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of BR0308071A publication Critical patent/BR0308071A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"INIBIDORES DA PROTEìNA FARNESIL TRANSFERASE COMO AGENTES ANTITUMORES". São apresentados novos compostos tricíclicos representados pela fórmula (1.0) e um sal ou solvato farmaceuticamente aceitável destes. Os compostos são úteis para a inibição da proteína farnesil transferase. Também são apresentados composições farmacêuticas compreendendo os compostos de fórmula 1.0. Da mesma forma são apresentados métodos de tratamento de câncer usando os compostos de fórmula 1.0.
BR0308071-4A 2002-02-27 2003-02-25 Inibidores da protéina farnesil transferase como agentes antitumores BR0308071A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
BR0308071A true BR0308071A (pt) 2004-12-21

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308071-4A BR0308071A (pt) 2002-02-27 2003-02-25 Inibidores da protéina farnesil transferase como agentes antitumores

Country Status (19)

Country Link
US (1) US7342016B2 (pt)
EP (1) EP1492772A1 (pt)
JP (1) JP2005525356A (pt)
KR (1) KR20040098004A (pt)
CN (1) CN100537542C (pt)
AR (1) AR039557A1 (pt)
AU (1) AU2003215389B2 (pt)
BR (1) BR0308071A (pt)
CA (1) CA2477328A1 (pt)
CO (1) CO5611194A2 (pt)
IL (1) IL163673A0 (pt)
MX (1) MXPA04008303A (pt)
NO (1) NO20044053L (pt)
NZ (1) NZ534809A (pt)
PE (1) PE20031038A1 (pt)
PL (1) PL372335A1 (pt)
RU (1) RU2004128465A (pt)
TW (1) TW200303867A (pt)
WO (1) WO2003072549A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180132969A (ko) * 2003-05-30 2018-12-12 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
KR20060057599A (ko) * 2003-08-07 2006-05-26 쉐링 코포레이션 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제
JP2008501031A (ja) * 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド ムスカリン受容体のモジュレーター
WO2005121140A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
US20070213340A1 (en) * 2006-01-19 2007-09-13 Kelly Joseph M Farnesyl protein transferase inhibitors
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
TW200831538A (en) * 2006-12-19 2008-08-01 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
CA2730190A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
CN115385892A (zh) * 2021-10-28 2022-11-25 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
EP0552245A1 (en) 1990-10-10 1993-07-28 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
ES2229340T3 (es) 1996-09-13 2005-04-16 Schering Corporation Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
CA2265764A1 (en) * 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful as fpt inhibitors
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
CA2294347C (en) 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
WO1998057948A1 (en) 1997-06-17 1998-12-23 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
CN1267290A (zh) 1997-06-17 2000-09-20 先灵公司 新的法呢基－蛋白转移酶的三环磺酰胺抑制剂
DE69825589T2 (de) 1997-06-17 2005-09-08 Schering Corp. Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
BR9916328A (pt) 1998-12-18 2001-10-02 Schering Corp Inibidores de transferase de farnesila
CN1326850C (zh) 1998-12-18 2007-07-18 先灵公司 三环类法尼基蛋白转移酶抑制剂
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
PT1255537E (pt) 2000-02-04 2006-09-29 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratar cancro da mama
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
JP2005515201A (ja) * 2001-12-03 2005-05-26 シェーリング　コーポレイション 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用
KR20060057599A (ko) * 2003-08-07 2006-05-26 쉐링 코포레이션 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제

Also Published As

Publication number Publication date
KR20040098004A (ko) 2004-11-18
AR039557A1 (es) 2005-02-23
IL163673A0 (en) 2005-12-18
TW200303867A (en) 2003-09-16
RU2004128465A (ru) 2005-09-27
NZ534809A (en) 2007-12-21
CA2477328A1 (en) 2003-09-04
WO2003072549A1 (en) 2003-09-04
US20040122018A1 (en) 2004-06-24
NO20044053L (no) 2004-11-26
JP2005525356A (ja) 2005-08-25
CN1630641A (zh) 2005-06-22
MXPA04008303A (es) 2005-11-23
AU2003215389A1 (en) 2003-09-09
PE20031038A1 (es) 2004-01-10
AU2003215389B2 (en) 2007-10-18
EP1492772A1 (en) 2005-01-05
CO5611194A2 (es) 2006-02-28
PL372335A1 (en) 2005-07-11
CN100537542C (zh) 2009-09-09
US7342016B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
BR0312408A (pt) Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
TW200613243A (en) Novel compounds
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
SE0302192D0 (sv) Novel compounds
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ATE238981T1 (de) Antitumorwirkstoffe
TWI268280B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
MX2009002998A (es) Derivado de pirazolopirimidina.
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
MY138124A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family
SV2002000211A (es) Derivados de higromicina ref. pc10726abcz/bb
DK1368336T3 (da) Thiophensubstituerede aminderivater som GlyT-1-inhibitorer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.